Enabling Protein Degradation Drug Discovery

Mark Treherne PhD

Chairman of the Board

Mark has over 25 years’ experience in drug discovery and development and has raised over £140 million for life science companies. He has served on the boards of fifteen private and public companies and is currently a director of Cyclofluidic, Domain Therapeutics, Talisman Therapeutics and Avilex Pharma. Previously, Mark was Chief Executive of Senexis and co-founded Cambridge Drug Discovery as Chief Executive in 1997, which he sold in 2001 to BioFocus plc, which was then subsequently acquired by Galapagos. Mark also worked at Pfizer to lead its neurodegeneration research team in the UK. Prior to that, Mark held a Senior Faculty position at the Biozentrum in Basel and has a B.Sc. in Physiology from St Andrews University (1983) and a Ph.D. in receptor neuropharmacology from the University of Cambridge (1987).